Baneocin, powder 250 me/g+5000 me/g 10 g

Pharmacodynamics

Baneocin is a combined antibacterial drug for topical use.

Baneocin contains two bactericidal antibiotics: neomycin and bacitracin.

Bacitracin is a polypeptide antibiotic that inhibits the synthesis of the bacterial cell membrane.

Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis.

Bacitracin is active against Gram-positive microorganisms such as beta-hemolytic streptococci, staphylococci, and some Gram-negative pathogens. Resistance to bacitracin is extremely rare.

Neomycin is effective against Gram-positive and Gram-negative microorganisms.

The combination of the two agents has achieved a broad spectrum of the drug and synergistic action against a number of microorganisms, such as Staphylococcus aureus.

Pharmacokinetics

The active ingredients are generally not absorbed (even by damaged skin), but high concentrations are present in the skin.

Baneocin is well tolerated. Tissue tolerance is rated as excellent, no inactivation by biological products, blood and tissue components has been noted. If the drug is applied to large areas of skin lesions, the possibility of absorption of the drug and its consequences must be taken into account.

Indications

Baneocin is indicated for use in infections caused by microorganisms sensitive to neomycin and/or bacitracin.

Active ingredient

Composition

Active ingredients:

Zinc-bacitracin 250 IU,

Neomycin sulfate 5000 IU (5 mg);

Associates:

Powder base sterilized (corn starch containing no more than 2% magnesium oxide)

How to take, the dosage

Externally. It is possible to apply without touching the affected surface with hands. The powder is applied in a thin layer on the affected areas 2 – 4 times a day in adults and children; if advisable – under a bandage. The area of powder application should not exceed 1% of the body surface area (which corresponds to the size of the patient’s palm).

The duration of treatment should not exceed 7 days.

Patients with impaired liver and/or kidney function.

When using doses much higher than recommended, the possibility of nephro- and/or ototoxic changes must be considered because of the increased risk of possible absorption of the active ingredients, especially in patients with impaired hepatic and/or renal function. Appropriate urine and blood tests or audiometric studies are recommended.

Patients of advanced age (65 years and older).

Dose adjustment in elderly patients is not necessary.

Interaction

In case of systemic absorption of the active ingredients of the drug, concomitant use of cephalosporins or aminoglycoside antibiotics may increase the likelihood of nephrotoxic reactions.

The simultaneous use of Baneocin® powder with diuretics such as etacrynic acid or furosemide may provoke ototoxic and nephrotoxic effects.

The absorption of the active ingredients of Baneocin® may increase the effects of neuromuscular conduction blockade in patients receiving narcotics, anesthetics and/or muscle relaxants.

Special Instructions

When used in doses significantly higher than recommended, due to possible absorption of Baneocin, special attention should be paid to symptoms indicating nephro- and/or ototoxic reactions.

Because the risk of toxic effects increases with decreased liver and/or renal function, blood and urine tests should be performed in patients with hepatic and/or renal impairment along with audiometric testing before and during therapy with Baneocin.

If absorption of Baneocin occurs, attention should be paid to potential blockade of neuromuscular conduction, especially in patients with acidosis, concomitant severe myasthenia gravis or other neuromuscular diseases.

In long-term treatment, attention should be paid to the possible growth of resistant microorganisms. Appropriate treatment should be prescribed in these situations.

In children, patients with compromised liver or kidney function, as well as patients with a large surface area to be treated, prolonged use and deep skin lesions, it is recommended that a physician be consulted in advance.

Patients who develop an allergy or superinfection should have the drug discontinued.

Contraindications

With caution:

Side effects

According to the World Health Organization (WHO), adverse effects are classified according to their frequency of development as follows: very frequently (≥1/10), frequently (≥1/100 to < 1/10), infrequently (≥1/1000 to < 1/100), rarely (≥1/10000 to < 1/1000), very rarely (< 1/10000); frequency unknown – it was not possible to determine the incidence based on available data. Baneocin® is generally well tolerated when used externally.

Overdose

Pregnancy use

The use of Baneocin during pregnancy and breastfeeding is possible only after consultation with a physician, if the expected benefits to the mother exceed the potential risk to the fetus and the baby.